340 related articles for article (PubMed ID: 33002863)
21. Prognostic implications of the subcellular localization of survivin in glioblastomas treated with radiotherapy plus concomitant and adjuvant temozolomide.
Saito T; Sugiyama K; Takeshima Y; Amatya VJ; Yamasaki F; Takayasu T; Nosaka R; Muragaki Y; Kawamata T; Kurisu K
J Neurosurg; 2018 Mar; 128(3):679-684. PubMed ID: 28430038
[TBL] [Abstract][Full Text] [Related]
22. Correlation Between the Residual Tumor Volume, Extent of Tumor Resection, and O
Sharma M; Bellamkonda S; Mohapatra S; Meola A; Jia X; Mohammadi A; Angelov L; Barnett GH; Vogelbaum M; Ahluwalia MS
World Neurosurg; 2018 Aug; 116():e147-e161. PubMed ID: 29709748
[TBL] [Abstract][Full Text] [Related]
23. Treatment of elderly patients with glioblastoma: a systematic evidence-based analysis.
Zarnett OJ; Sahgal A; Gosio J; Perry J; Berger MS; Chang S; Das S
JAMA Neurol; 2015 May; 72(5):589-96. PubMed ID: 25822375
[TBL] [Abstract][Full Text] [Related]
24. Low MGMT digital expression is associated with a better outcome of IDH1 wildtype glioblastomas treated with temozolomide.
Gomes I; Moreno DA; Dos Reis MB; da Silva LS; Leal LF; Gonçalves GM; Pereira CA; Oliveira MA; de Medeiros Matsushita M; Reis RM
J Neurooncol; 2021 Jan; 151(2):135-144. PubMed ID: 33400009
[TBL] [Abstract][Full Text] [Related]
25. Hypofractionated radiotherapy followed by adjuvant chemotherapy with temozolomide in elderly patients with glioblastoma.
Minniti G; De Sanctis V; Muni R; Rasio D; Lanzetta G; Bozzao A; Osti MF; Salvati M; Valeriani M; Cantore GP; Maurizi Enrici R
J Neurooncol; 2009 Jan; 91(1):95-100. PubMed ID: 18758912
[TBL] [Abstract][Full Text] [Related]
26. Radiotherapy plus concomitant temozolomide in primary gliosarcoma.
Adeberg S; Bernhardt D; Harrabi SB; Diehl C; Koelsche C; Rieken S; Unterberg A; von Deimling A; Debus J
J Neurooncol; 2016 Jun; 128(2):341-8. PubMed ID: 27025857
[TBL] [Abstract][Full Text] [Related]
27. MGMT gene promoter methylation as a potent prognostic factor in glioblastoma treated with temozolomide-based chemoradiotherapy: a single-institution study.
Kim YS; Kim SH; Cho J; Kim JW; Chang JH; Kim DS; Lee KS; Suh CO
Int J Radiat Oncol Biol Phys; 2012 Nov; 84(3):661-7. PubMed ID: 22414280
[TBL] [Abstract][Full Text] [Related]
28. Radiotherapy plus temozolomide in elderly patients with glioblastoma: a "real-life" report.
Biau J; Chautard E; De Schlichting E; Dupic G; Pereira B; Fogli A; Müller-Barthélémy M; Dalloz P; Khalil T; Dillies AF; Durando X; Godfraind C; Verrelle P
Radiat Oncol; 2017 Dec; 12(1):197. PubMed ID: 29212499
[TBL] [Abstract][Full Text] [Related]
29. Prediction of Outcomes with a Computational Biology Model in Newly Diagnosed Glioblastoma Patients Treated with Radiation Therapy and Temozolomide.
Rahman R; Trippa L; Alden S; Fell G; Abbasi T; Mundkur Y; Singh NK; Talawdekar A; Husain Z; Vali S; Ligon KL; Wen PY; Alexander BM
Int J Radiat Oncol Biol Phys; 2020 Nov; 108(3):716-724. PubMed ID: 32417407
[TBL] [Abstract][Full Text] [Related]
30. Outcomes in Elderly Patients with Glioblastoma Multiforme Treated with Short-Course Radiation Alone Compared to Short-Course Radiation and Concurrent and Adjuvant Temozolomide Based on Performance Status and Extent of Resection.
Mir T; Pond G; Greenspoon JN
Curr Oncol; 2021 Jun; 28(4):2399-2408. PubMed ID: 34206775
[TBL] [Abstract][Full Text] [Related]
31. Survival Outcomes of Elderly Patients With Glioblastoma Multiforme in Their 75th Year or Older Treated With Adjuvant Therapy.
Harris G; Jayamanne D; Wheeler H; Gzell C; Kastelan M; Schembri G; Brazier D; Cook R; Parkinson J; Khasraw M; Louw S; Back M
Int J Radiat Oncol Biol Phys; 2017 Jul; 98(4):802-810. PubMed ID: 28602411
[TBL] [Abstract][Full Text] [Related]
32. MGMT-Positive vs MGMT-Negative Patients With Glioblastoma: Identification of Prognostic Factors and Resection Threshold.
Katsigiannis S; Grau S; Krischek B; Er K; Pintea B; Goldbrunner R; Stavrinou P
Neurosurgery; 2021 Mar; 88(4):E323-E329. PubMed ID: 33432978
[TBL] [Abstract][Full Text] [Related]
33. Is MGMT promoter methylation to be considered in the decision making for recurrent surgery in glioblastoma patients?
Pala A; Schmitz AL; Knoll A; Schneider M; Hlavac M; König R; Wirtz CR; Coburger J
Clin Neurol Neurosurg; 2018 Apr; 167():6-10. PubMed ID: 29425743
[TBL] [Abstract][Full Text] [Related]
34. Predictive value of MGMT promoter methylation on the survival of TMZ treated
Chai R; Li G; Liu Y; Zhang K; Zhao Z; Wu F; Chang Y; Pang B; Li J; Li Y; Jiang T; Wang Y
Cancer Biol Med; 2021 Feb; 18(1):272-282. PubMed ID: 33628600
[TBL] [Abstract][Full Text] [Related]
35. Surgery for Glioblastoma in Light of Molecular Markers: Impact of Resection and MGMT Promoter Methylation in Newly Diagnosed IDH-1 Wild-Type Glioblastomas.
Gessler F; Bernstock JD; Braczynski A; Lescher S; Baumgarten P; Harter PN; Mittelbronn M; Wu T; Seifert V; Senft C
Neurosurgery; 2019 Jan; 84(1):190-197. PubMed ID: 29617848
[TBL] [Abstract][Full Text] [Related]
36. Glioblastoma Treatment in the Elderly.
Okada M; Miyake K; Tamiya T
Neurol Med Chir (Tokyo); 2017 Dec; 57(12):667-676. PubMed ID: 29081442
[TBL] [Abstract][Full Text] [Related]
37. Genetic analysis in patients with newly diagnosed glioblastomas treated with interferon-beta plus temozolomide in comparison with temozolomide alone.
Natsume A; Aoki K; Ohka F; Maeda S; Hirano M; Adilijiang A; Motomura K; Sumi M; Nishikawa R; Narita Y; Muragaki Y; Maruyama T; Ito T; Beppu T; Nakamura H; Kayama T; Sato S; Nagane M; Mishima K; Nakasu Y; Kurisu K; Yamasaki F; Sugiyama K; Onishi T; Iwadate Y; Terasaki M; Kobayashi H; Matsumura A; Ishikawa E; Sasaki H; Mukasa A; Matsuo T; Hirano H; Kumabe T; Shinoura N; Hashimoto N; Aoki T; Asai A; Abe T; Yoshino A; Arakawa Y; Asano K; Yoshimoto K; Shibui S; Okuno Y; Wakabayashi T;
J Neurooncol; 2020 May; 148(1):17-27. PubMed ID: 32367437
[TBL] [Abstract][Full Text] [Related]
38. Postoperative neoadjuvant temozolomide before radiotherapy versus standard radiotherapy in patients 60 years or younger with anaplastic astrocytoma or glioblastoma: a randomized trial.
Malmström A; Poulsen HS; Grønberg BH; Stragliotto G; Hansen S; Asklund T; Holmlund B; Łysiak M; Dowsett J; Kristensen BW; Söderkvist P; Rosell J; Henriksson R;
Acta Oncol; 2017 Dec; 56(12):1776-1785. PubMed ID: 28675067
[TBL] [Abstract][Full Text] [Related]
39. Standard dose and dose-escalated radiation therapy are associated with favorable survival in select elderly patients with newly diagnosed glioblastoma.
Jackson WC; Tsien CI; Junck L; Leung D; Hervey-Jumper S; Orringer D; Heth J; Wahl DR; Spratt DE; Cao Y; Lawrence TS; Kim MM
J Neurooncol; 2018 May; 138(1):155-162. PubMed ID: 29388034
[TBL] [Abstract][Full Text] [Related]
40. Concurrent Chemoradiotherapy with Temozolomide Followed by Adjuvant Temozolomide for Newly Diagnosed Glioblastoma Patients: A Retrospective Multicenter Observation Study in Korea.
Kim BS; Seol HJ; Nam DH; Park CK; Kim IH; Kim TM; Kim JH; Cho YH; Yoon SM; Chang JH; Kang SG; Kim EH; Suh CO; Jung TY; Lee KH; Kim CY; Kim IA; Hong CK; Yoo H; Kim JH; Kang SH; Kang MK; Kim EY; Kim SH; Chung DS; Hwang SC; Song JH; Cho SJ; Lee SI; Lee YS; Ahn KJ; Kim SH; Lim DH; Gwak HS; Lee SH; Hong YK
Cancer Res Treat; 2017 Jan; 49(1):193-203. PubMed ID: 27384161
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]